Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

The company founded in 1963 - which influenced hundreds of millions of people in the US and around the world - has filed for ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...